Alpha-interferon and lymphokine-activated killer cells in hairy cell leukemia
- PMID: 3374170
Alpha-interferon and lymphokine-activated killer cells in hairy cell leukemia
Abstract
Lymphokine-activated killer (LAK) cell activity generated from peripheral blood was tested in 6 patients with typical hairy cell leukemia, 3 not on treatment with alpha-interferon (alpha-IFN) and 3 receiving therapy. In all cases, substantial killing of the LAK-sensitive target Daudi was observed, but hairy cells, whether or not they had been pretreated with alpha-IFN, were uniformly resistant to LAK lysis. The hairy cells were also resistant to LAK cell killing generated from normal peripheral blood mononuclear cells. alpha-IFN added at various times during LAK generation had little or no effect on LAK activity. It is concluded that LAK cells are not important in mediating the beneficial effects of alpha-IFN in hairy cell leukemia.
Similar articles
-
The beneficial effects of alpha-interferon in hairy cell leukemia are not attributable to NK cell-mediated cytotoxicity.Leukemia. 1987 Apr;1(4):372-6. Leukemia. 1987. PMID: 3669763
-
Hairy cell leukemia cells are relatively NK-insensitive targets.Pathology. 1988 Oct;20(4):361-5. doi: 10.3109/00313028809085220. Pathology. 1988. PMID: 2977221
-
Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity.Cancer Res. 1993 Aug 1;53(15):3555-60. Cancer Res. 1993. PMID: 7687924
-
Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy.Cancer Res. 1992 Mar 1;52(5):1056-66. Cancer Res. 1992. PMID: 1737364 Review.
-
Lymphokine-activated killer cells, natural killer cells and cytokines.Curr Opin Immunol. 1991 Feb;3(1):49-55. doi: 10.1016/0952-7915(91)90076-d. Curr Opin Immunol. 1991. PMID: 2054113 Review.
Cited by
-
Hairy cell sensitivity to the lysis in vitro. Role of the anti-CD3 antibody in generating a susceptibility to the lysis.Cancer Immunol Immunother. 1989;30(4):254-6. doi: 10.1007/BF01665013. Cancer Immunol Immunother. 1989. PMID: 2532060 Free PMC article.
-
2',5'-Oligoadenylate synthetase levels in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b do not correlate with clinical response.Br J Cancer. 1995 Dec;72(6):1525-30. doi: 10.1038/bjc.1995.541. Br J Cancer. 1995. PMID: 8519671 Free PMC article.